×
About 558 results
Atopic dermatitis/Eczema | DermNet NZ
https://www.dermnetnz.org/topics/atopic-dermatitis/

Jun 24th, 2019 - Atopic dermatitis is a chronic, itchy skin condition that is very common in children but may occur at any age. It is also known as eczema and atopic eczema and was formerly known as Besnier prurigo. It is the most common form of dermatitis. Atopic dermatitis usually occurs in people who have an 'atopic tendency'. This means they may develop any or all of three closely linked conditions; atop...

GRASTEK® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use
https://www.grastek.com/grastek-healthcare-providers/

Find studies, dosing instructions and the safety and tolerability profile for GRASTEK®. View Safety Info & Boxed Warning.

Coronavirus Disease 2019: Resources (AAO-HNS)
https://www.entnet.org/content/coronavirus-disease-2019-resources
American Academy of Otolaryngology - Head & Neck Surgery;

Mar 22nd, 2020 - Anosmia, Hyposmia, and Dysgeusia Symptoms of Coronavirus Disease. Anecdotal evidence is rapidly accumulating from sites around the world that anosmia and dysgeusia are significant symptoms associated with the COVID-19 pandemic. Anosmia, in particular, has been seen in patients ultimately testing positive for the coronavirus with no other symptoms. We propose that these symptoms be added to the...

SLIT tablet during pollen season improves symptoms of allergic rhinitis
https://www.mdedge.com/chestphysician/article/219239/pulmonology/slit-tablet-during-pollen-season-improves-symptoms?channel=284
Jeff Craven, MDedge News

Mar 18th, 2020 - Patients with allergic rhinitis receiving oral tree sublingual immunotherapy (SLIT) during pollen season showed improvement in their symptoms, according to recent research released as an abstract for the annual meeting of the American Academy of Allergy, Asthma & Immunology. Photo courtesy Oak Ridge National Laboratory Tree pollen season is generally considered to be between February and June,.

Marijuana Allergies on the Rise
https://www.medscape.com/viewarticle/926358

Mar 5th, 2020 - "Cannabis sativa is a weed and it causes reactions just like any other pollen allergy," said William Silvers, MD, from the University of Colorado School of Medicine in Aurora. Silvers' clinic began to see people with allergic reactions to the plant after the increase in direct exposure that accompanied the legalization of recreational marijuana in Colorado. For people with allergic tendencies, ...

FDA issues stronger warning on neuropsychiatric event risk linked to montelukast
https://www.mdedge.com/familymedicine/article/218474/asthma/fda-issues-stronger-warning-neuropsychiatric-event-risk-linked?channel=39313
CHEST Physician; Lucas Franki

Mar 5th, 2020 - The Food and Drug Administration has issued a Drug Safety Communication that strengthens existing warnings about serious mood- and behavior-related changes associated with montelukast (Singulair), a prescription drug for asthma and allergy. The new boxed warning advises health care providers to avoid prescribing montelukast for patients with mild symptoms, particularly those with allergic rhini.

Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning - Due to Restricting Use for Allergic Rhinitis | FDA
https://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use

[Posted 03/04/2020] AUDIENCE: Patient, Health Professional, Pharmacy, Allergy and Immunology ISSUE: FDA is strengthening existing warnings about serious behavior and mood-related changes with montelukast (Singulair and generics), which is a prescription medicine for asthma and allergy. FDA is taking this action after a review of available information that led us to reevaluate the benefits and r...

FDA Adds Boxed Warning to Montelukast Over Mental Health Risks
https://www.medscape.com/viewarticle/926271

Mar 3rd, 2020 - The US Food and Drug Administration (FDA) is strengthening existing warnings about serious behavior and mood-related changes with montelukast (Singulair; Merck and generics), which is used to treat asthma and allergy. The agency will add a boxed warning to montelukast advising healthcare providers to avoid prescribing montelukast for patients with mild symptoms, particularly those with allergic...

Which children are at greatest risk for atopic dermatitis?
https://www.mdedge.com/pediatrics/article/214740/atopic-dermatitis/which-children-are-greatest-risk-atopic-dermatitis/page/0/1?channel=189

Dec 24th, 2019 - The meta-analysis showed that a parental history of atopic dermatitis was associated with a 3. 3-fold greater risk of atopic dermatitis in the offspring than in families without a parental history of atopy.

Active Ingredient in OTC Inhaler a 'New' Drug of Abuse
https://www.medscape.com/viewarticle/922914

Dec 18th, 2019 - SAN DIEGO ― The active ingredient in an over-the-counter nasal decongestant appears to be re-emerging as a "new" drug of abuse, addiction experts warn. Propylhexedrine (multiple brands) is indicated for relief of nasal congestion from colds, allergic rhinitis, and sinusitis. Previously considered to have low potential for abuse, new research suggests the opposite may be true. Dr Nikhil Teja "Pr...

Dysregulated sleep is common in children with eosinophilic esophagitis
https://www.mdedge.com/clinicianreviews/article/209671/sleep-medicine/dysregulated-sleep-common-children-eosinophilic?channel=296
Michele G. Sullivan

Oct 8th, 2019 - Children with eosinophilic esophagitis often experience respiratory and motor disturbances during sleep, which appear related to dysregulated sleep architecture, Rasintra Siriwat, MD, and colleagues have ascertained. ©Alex Vasilev/Fotolia.

A 36-Year-Old Woman With a Worsening Cough and Hearing Loss
https://www.medscape.com/viewarticle/917371

Sep 4th, 2019 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case that you would like to suggest for a future Case Challenge, please ...

Granuloma Annulare Presenting as Firm Nodules on the Forehead and Scalp in a Child
https://www.mdedge.com/dermatology/article/206981/pediatrics/granuloma-annulare-presenting-firm-nodules-forehead-and-scalp?channel=271
Rachel Laarman, MD, Tiffany J. Herd, MD et. al.

Aug 26th, 2019 - To the Editor: A 3. 5-year-old boy presented with asymptomatic subcutaneous nodules on the left side of the forehead and frontal scalp of approximately 6 months’ duration.

5 Practical Pointers on Allergic Rhinitis
https://www.medscape.com/viewarticle/912058

Apr 24th, 2019 - Allergic rhinitis is common, and for seasonal allergy sufferers it's predictable. So why is it such a cause of misery when many over-the-counter allergy medications are available? The answer may lie in an incorrect diagnosis or an ineffective treatment. Is It Really Allergic Rhinitis? During pollen season, I see two types of patients in my practice: those with seasonal allergic rhinitis and tho...

Allergic Rhinitis: Osmosis Study Video
https://www.medscape.com/viewarticle/910183

Mar 21st, 2019 - What is allergic rhinitis? Allergic rhinitis is inflammation of the nose and eyes, which develops because of a type 1 hypersensitivity reaction. This video covers the basics of allergic rhinitis, including key components of diagnosis and treatment. For more study tools from Osmosis on Medscape, see our collection here.

College News Networks
https://www.mdedge.com/chestphysician/article/191181/society-news/college-news-networks/page/0/1

Jan 14th, 2019 - Interprofessional Team Difficult-to-control asthma, defined as: uncontrolled asthma despite use of maximum dose inhaled corticosteroids or chronic oral corticosteroids with daily asthma symptoms, frequent exacerbations, and/or hospitalization results in a substantial medical and financial burden with a resultant decrease in quality-of-life. Extrapulmonary co-morbidities, such as obesity, nicoti.

Adult atopic dermatitis is fraught with dermatologic comorbidities
https://www.mdedge.com/familymedicine/article/192496/atopic-dermatitis/adult-atopic-dermatitis-fraught-dermatologic?channel=39313
MDedge Dermatology; Bruce Jancin

Jan 11th, 2019 - PARIS – Adults with atopic dermatitis (AD) are at sharply increased risk for a broad array of comorbid dermatologic conditions ranging from A to V: that is, from alopecia areata to vitiligo, and points in between, according to a large German national study. Bruce Jancin/MDedge News Nicole Zander These dermatologic comorbidities are in addition to already well established strong associations bet.

Gestational, umbilical cord vitamin D levels don’t predict atopic disease in offspring
https://www.mdedge.com/pediatrics/article/190119/obstetrics/gestational-umbilical-cord-vitamin-d-levels-dont-predict-atopic?channel=189
Jeff Craven

Dec 3rd, 2018 - Vitamin D levels measured in maternal sera during gestation and in umbilical cord blood were not predictive of the prevalence of eczema, food allergy, asthma and allergic rhinitis in children at ages 2 years and 5 years, according to study results published in the journal Allergy. copyright istock/Thinkstock Áine Hennessy, PhD, from the School of Food and Nutritional Sciences at the University.

Allergy Testing in Dermatology and Beyond
https://www.mdedge.com/dermatology/article/189678/practice-management/allergy-testing-dermatology-and-beyond?channel=28253
Ashley D. Lundgren, MD

Nov 28th, 2018 - Allergy testing typically refers to evaluation of a patient for suspected type I or type IV hypersensitivity. 1,2 The possibility of type I hypersensitivity is raised in patients presenting with food allergies, allergic rhinitis, asthma, and immediate adverse reactions to medications, whereas type IV hypersensitivity is suspected in patients with eczematous eruptions, delayed adverse cutaneous r.

New Drug Combinations for Asthma, COPD at CHEST 2018
https://www.medscape.com/viewarticle/902774

Sep 30th, 2018 - SAN ANTONIO — New combinations of known and experimental drugs will be explored at the American College of Chest Physicians Annual Meeting as the pharmaceutical search for better control of asthma and chronic obstructive pulmonary disease (COPD) continues. The combination of montelukast plus levocetirizine for the treatment of asthma control in patients with concomitant allergic rhinitis will b...

Fast Five Quiz: Test Your Knowledge About Fall Allergies
https://www.medscape.com/viewarticle/884925

Sep 20th, 2018 - Although many people associate allergies with the growth and development of plants in spring and summer, allergic symptoms are very common in the fall as well. Ragweed is the biggest allergy trigger during the fall season, but mold, dust mites, and other causes are also responsible. Allergic rhinitis, also known as "hay fever," is often associated with symptoms that flare during autumn. Accordi...

Advise parents on validity of AD-associated conditions
https://www.mdedge.com/pediatrics/article/172058/atopic-dermatitis/advise-parents-validity-ad-associated-conditions?channel=189
Heidi Splete

Aug 7th, 2018 - Atopic dermatitis is becoming more prevalent in the industrialized world, along with other atopic disorders, including allergic rhinitis and asthma, according to Douglas W. Kress, MD, of the department of dermatology at the University of Pittsburgh.

Pediatrics Clinical Practice Guidelines: 2018 Midyear Review
https://www.medscape.com/viewarticle/898701

Jul 9th, 2018 - Allergy Immunotherapy European Academy of Allergy and Clinical Immunology A 3-year course of allergen immunotherapy (AIT) (subcutaneous immunotherapy [SCIT] or sublingual immunotherapy [SLIT]) can be considered in children with moderate to severe allergic rhinitis (AR) and grass/birch pollen allergy that are not sufficiently controlled with optimal pharmacotherapy, for short-term (ie, up to 2 y...

Atopic Dermatitis: Five Promising Targeted Therapies
https://www.medscape.com/viewarticle/898282

Jun 25th, 2018 - Promising New Therapies for Atopic Dermatitis Atopic dermatitis (AD) is a T-cell-driven, chronic inflammatory skin disease with a prevalence of up to 10% in adults and 25% in children.[1,2] Classic AD presents during infancy with recurrent facial dermatitis, morphing during childhood into chronic inflammatory flexural patches and lichenified plaques. Characteristics include pruritus, associated...

Debunking Atopic Dermatitis Myths: Should You Use Systemic Therapy?
https://www.mdedge.com/dermatology/article/167905/atopic-dermatitis/debunking-atopic-dermatitis-myths-should-you-use?channel=189

Jun 12th, 2018 - Myth: Because atopic dermatitis is skin-deep, systemic therapy is unnecessary. Although atopic dermatitis (AD) primarily is known as a skin condition, recent research has indicated that it may be the start of the “atopic march” leading to the development of 1 or more other atopic conditions with multiorgan involvement.

Delayed Cutaneous Reactions to Iodinated Contrast
https://www.mdedge.com/dermatology/article/167493/contact-dermatitis/delayed-cutaneous-reactions-iodinated-contrast?channel=199
Daniel R. Mazori, MD, Arielle R. Nagler, MD et. al.

Jun 6th, 2018 - Case Report A 67-year-old woman with a history of allergic rhinitis presented in the spring with a pruritic eruption of 2 days’ duration that began on the abdomen and spread to the chest, back, and bilateral arms. Six days prior to the onset of the symptoms she underwent computed tomography (CT) of the abdomen and pelvis to evaluate abdominal pain and peripheral eosinophilia.

Allergies and Asthma May Be Linked to Mental Health
https://www.medscape.com/viewarticle/895916

Apr 29th, 2018 - NEW YORK (Reuters Health) - People who suffer from asthma and allergic rhinitis have an increased risk for developing a psychiatric disorder, and assessing their emotional condition and monitoring their mental health might be worthwhile, say researchers from Taiwan. Asthma, allergic rhinitis and atopic dermatitis - nicknamed the three "A's" - are among some of the most common allergic diseases....

Recurrence Rate Low in Pediatric Vasculitis
https://www.medpagetoday.com/rheumatology/generalrheumatology/72419

Apr 18th, 2018 - Action Points Note that this cohort study from Taiwan identified risk factors for recurrent Henoch-Schönlein purpura among children with an initial bout of the disease. Steroid use and nasal involvement were important predictors of recurrence. Fewer than 20% of children who developed Henoch-Schönlein purpura (HSP) had a recurrence of this vasculitis, but those who did have a second or third epi...

Key Pediatric Clinical Practice Guidelines in 2017
https://www.medscape.com/viewarticle/890833

Jan 9th, 2018 - In This Issue This issue of Key Pediatric Clinical Practice Guidelines in 2017 contains 15 sets of Guidelines and Recommendations released during 2017. You can scroll through the guidelines sequentially, from Anaphylaxis to Seasonal Allergic Rhinitis, or you can choose individual guidelines listed alphabetically in the scroll bar. For complete guidelines from previous months, click Previous Gui...

News Quiz: Top Pediatrics Stories of 2017
https://www.medscape.com/viewarticle/889864

Dec 11th, 2017 - Don't Use Tramadol and Codeine in Kids Under 12, FDA Warns Earlier this year, the US Food and Drug Administration warned that children younger than 12 years should not take tramadol (multiple brands) or codeine. Tramadol is indicated for pain, whereas codeine is for both pain and cough. Montelukast Tied to Psychiatric Adverse Events in Kids, Adults Montelukast (Singulair, Merck) is used in main...

Allergy Experts: Single Drug Best for Allergic Rhinitis
https://www.medpagetoday.com/allergyimmunology/allergy/69158

Nov 9th, 2017 - When it comes to treating seasonal allergies, one drug is often better than two: updated guidelines for the treatment of teen and adult patients with allergic rhinitis recommend initial treatment with an intranasal corticosteroid alone without an oral antihistamine. The guidelines, appearing in the Annals of Allergy, Asthma and Immunology, follow a comprehensive review by a joint task force of ...

New Guidelines for Allergic Rhinitis Change Treatment
https://www.medscape.com/viewarticle/888269

Nov 8th, 2017 - An update of recommendations for the treatment of seasonal allergic rhinitis (SAR) in adolescents and adults, issued by members of the Joint Task Force on Practice Parameters (JTFPP), changes initial treatment strategies and aims to reduce unnecessary cost to patients and variations in care. The previous guidelines were issued in 2008 by the JTFPP of the American Academy of Allergy, Asthma, & I...

Latest on dupilumab for atopic dermatitis: The who and how
https://www.mdedge.com/dermatology/article/147509/atopic-dermatitis/latest-dupilumab-atopic-dermatitis-who-and-how?channel=53
Bruce Jancin

Sep 20th, 2017 - GENEVA – The novel interleukin-4 and IL-13 signaling blocker dupilumab displayed consistently strong efficacy across all patient subgroups in a new analysis from the landmark 52-week CHRONOS trial, Andrew Blauvelt, MD, reported at the annual congress of the European Academy of Dermatology and Venereology. “Dupilumab with concomitant topical corticosteroids improved signs and symptoms of atopic.

Is Response to Allergy Immunotherapy Predictable?
https://www.medscape.com/viewarticle/880011

May 18th, 2017 - Background Allergen immunotherapy (AIT) has been around for over 100 years, and plenty of advances have occurred since the first report of successful grass pollen immunotherapy in 1911.[1] Several studies and meta-analyses support the efficacy of both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for allergic rhinitis and asthma.[2] One of the great advantages of AIT is ...

Do Spring Allergies Bring Thoughts of Suicide? (The Atlantic)
https://www.medpagetoday.com/allergyimmunology/allergy/64715

Apr 21st, 2017 - Suicides peak in the spring and early summer, at a time when the air can be full of tree pollen, and some researchers believe the link may not be simple coincidence. It's not merely the misery of allergic rhinitis that underlies the association, according to a report in The Atlantic, but an inflammatory reaction involving cytokine release caused by allergen exposure that can disrupt the nervous...

Prescription to Over-the-Counter (OTC) Switch List
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm106378.htm

January 1 through September 1, 2017 NDA Drug Name Purpose Approval Date NDA 209089 Xyzal Allergy 24HR (levocetirizine dihydrochloride) tablets Allergic rhinitis and perennial allergic rhinitis AP 1-31-17 NDA 209090 Xyzal Allergy 24HR (levocetirizine dihydrochloride) solution Allergic rhinitis and perennial allergic rhinitis AP 1-31-17 January 1 through December 31, 2016 NDA Drug Name Purpose Ap...

2020 Drug Safety Communications
http://www.fda.gov/drugs/drug-safety-and-availability/2020-drug-safety-communications

FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis 3/4/2020 FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market 2/13/2020 FDA strengthens warning that untreated constipation caused by schizophrenia medicine clozapine (Clozaril) can le...

FDA Drug Safety Podcasts
http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-podcasts

The FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and Research (CDER). They provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications.     Latest Drug Safety Podcasts Title Date Link to Podcast Link to Transcript FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug monteluk...

FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis
http://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug

3-4-2020 FDA Drug Safety Communication What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is strengthening existing warnings about serious behavior and mood-related changes with montelukast (Singulair and generics), which is a prescription medicine for asthma and allergy. We are taking this action after a review of available information led us to reevaluate the b...

Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning - Due to Restricting Use for Allergic Rhinitis
http://www.fda.gov/safety/medical-product-safety-information/singulair-montelukast-and-all-montelukast-generics-strengthened-boxed-warning-due-restricting-use

[Posted 03/04/2020] AUDIENCE: Patient, Health Professional, Pharmacy, Allergy and Immunology ISSUE: FDA is strengthening existing warnings about serious behavior and mood-related changes with montelukast (Singulair and generics), which is a prescription medicine for asthma and allergy. FDA is taking this action after a review of available information that led us to reevaluate the benefits and r...

One Hundred Case Series of Vocal Cord Dysfunction in a Military Treatment Facility
https://www.mdedge.com/fedprac/article/132553/hospital-medicine/one-hundred-case-series-vocal-cord-dysfunction-military/page/0/3?channel=104

Mar 14th, 2017 - Conclusion Vocal cord dysfunction remains a difficult diagnosis to treat, because multiple comorbidities likely contribute to the diagnosis. This retrospective case series attempted to compile common themes and noted that most of the patients had 2 or more risk factors of smoking, allergic rhinitis, GERD, or mental health diagnoses.

FDA approves sublingual immunotherapy for dust mite allergies
https://www.mdedge.com/chestphysician/article/132588/pulmonology/fda-approves-sublingual-immunotherapy-dust-mite-allergies?channel=27979
Jennie Smith, MDedge News

Mar 2nd, 2017 - The Food and Drug administration has approved a sublingual immunotherapy to treat nasal inflammation caused by dust mite allergy. Odactra (Merck, Sharp & Dohme) had been approved in adults aged 18-65 years, with allergic rhinitis with or without conjunctivitis.

SLIT for Dust Mite Allergy Wins FDA Approval
https://www.medpagetoday.com/allergyimmunology/allergy/63516

Mar 1st, 2017 - WASHINGTON -- The FDA approved a sublingual immunotherapy (SLIT) product to treat house dust mite allergies, the agency said Wednesday. Odactra comprises dust mite allergens and is designed to induce tolerance in individuals with allergic rhinitis, with or without conjunctivitis. The product is a rapid-dissolving tablet placed under the tongue once daily, approved for adult (ages 18-65) use onl...

Odactra First Sublingual Therapy OK'd for House Dust Mite Allergy
https://www.medscape.com/viewarticle/876513

Feb 28th, 2017 - The US Food and Drug Administration (FDA) has approved Odactra (Merck, Sharp & Dohme Corp), the first sublingual allergen extract for the treatment of house dust mite–induced allergic rhinitis, with or without conjunctivitis in adults aged 18 through 65 years. "House dust mite allergic disease can negatively impact a person's quality of life," Peter Marks, MD, PhD, director of the FDA's Center ...

Two-Year SLIT Insufficient for Lasting Hay Fever Tolerance
https://www.medpagetoday.com/allergyimmunology/allergy/63129

Feb 14th, 2017 - Action Points Two years of sublingual immunotherapy did not permanently modify allergic responses and achieve long-term tolerance in patients with moderate to severe seasonal allergic rhinitis, according to a single-center, randomized, placebo-controlled study. Be aware that current guidelines recommend that at least 3 years of sublingual immunotherapy (SLIT) are required for induction of lon...

Allergic Rhinitis: 3 Years of Immunotherapy Needed
https://www.medscape.com/viewarticle/875799

Feb 13th, 2017 - Among patients with allergy to grass pollen, 2 years of sublingual immunotherapy for allergic rhinitis are no more effective than placebo at relieving symptoms 1 year after the end of treatment, a new study shows. The findings suggest that 3 years of treatment with sublingual immunotherapy are necessary for long-term control of moderate to severe allergic rhinitis, Guy W. Scadding, MBBS, PhD, a...

Fast Five Quiz: What Do You Know About Eczema?
https://www.medscape.com/viewarticle/873989

Jan 5th, 2017 - Eczema, or atopic dermatitis (AD), is a pruritic disease of unknown origin. It is characterized by pruritus, eczematous lesions, xerosis (dry skin), and lichenification (thickening of the skin and an increase in skin markings). AD may be associated with other atopic (immunoglobulin E [IgE]–associated) diseases (eg, acute allergic reaction to foods, asthma, urticaria, and allergic rhinitis). AD ...

Periostin level may indicate upper-airway disease in asthmatics
https://www.mdedge.com/familymedicine/article/115218/pulmonology/periostin-level-may-indicate-upper-airway-disease?channel=53
CHEST Physician; Sara Freeman

Oct 6th, 2016 - LONDON – Measuring serum levels of the extracellular protein periostin could help identify patients with asthma who have comorbid upper-airway disease, according to research from a late-breaking oral abstract presented at the annual congress of the European Respiratory Society. Periostin is known to be involved in the pathophysiology of upper-airway disease, linked to both airway remodeling and.

Dust Mite Allergens in Breast Milk Linked to Allergic Disease
https://www.medscape.com/viewarticle/868511

Sep 7th, 2016 - NEW YORK (Reuters Health) - Exposure to respiratory house dust mite (HDM) allergen in breast milk is associated with increased risk of allergic sensitization at five years of age, new findings show. The risk was strongest in children whose mothers had a history of allergic disease, Dr. Valerie Verhasselt of the University Nice Sophia Antipolis in Nice, France, and colleagues found. These childr...

Allergy Therapeutics says study fails to find hay fever therapy dose range
https://www.reuters.com/article/us-at-study/allergy-therapeutics-says-study-fails-to-find-hay-fever-therapy-dose-range-idUSKCN0ZD0VQ

Jun 27th, 2016 - (Reuters) - Drug developer Allergy Therapeutics Plc said a study on suitable doses of its therapy to treat grass allergic rhinitis, or hay fever, did not find a recommended dose for a late-stage trial. This is the second allergy therapy in two weeks to run into trouble, after Circassia Pharmaceuticals Plc said last week that its cat allergy treatment failed in a late-stage trial. Allergy Therap...

Cochrane Review Nixes Specific Allergen Immunotherapy for Atopic Dermatitis
https://www.mdedge.com/clinicianreviews/article/108564/dermatology/cochrane-review-nixes-specific-allergen-immunotherapy?channel=203
Bruce Jancin

Apr 23rd, 2016 - LOS ANGELES – A new Cochrane systematic review and meta-analysis has concluded there is no consistent evidence that specific allergen immunotherapy is beneficial in patients with atopic dermatitis, Dr. Herman H.

Cochrane Review nixes specific allergen immunotherapy for atopic dermatitis
https://www.mdedge.com/pediatrics/article/108278/atopic-dermatitis/cochrane-review-nixes-specific-allergen-immunotherapy?channel=189
Bruce Jancin

Apr 23rd, 2016 - LOS ANGELES – A new Cochrane systematic review and meta-analysis has concluded there is no consistent evidence that specific allergen immunotherapy is beneficial in patients with atopic dermatitis, Dr. Herman H.

Childhood Allergies May Predict Internalizing Behaviors
https://www.medscape.com/viewarticle/856880

Jan 6th, 2016 - Children with allergic rhinitis and allergic persistent wheezing at age 4 years may have increased risk for internalizing behaviors at age 7 years, and the risk appears to be associated with the number of allergic diseases, according to a longitudinal study published in the January 2016 issue of Pediatrics. "Allergic diseases in childhood have been associated with internalizing disorders, inclu...

Allergies may boost chances of anxiety or depression symptoms
https://www.reuters.com/article/us-health-kids-allergies-depression/allergies-may-boost-chances-of-anxiety-or-depression-symptoms-idUSKBN0UC1TW20151229

Dec 29th, 2015 - (Reuters Health) - Kids who have allergies at an early age are more likely than others to also have problems with anxiety and depression, according to a new study. As the number of allergies increase, so do internalizing behavior scores, the researchers found. Internalizing behaviors include disorders, like anxiety or depression, that develop when people keep their problems to themselves, or “i...

News Quiz: 2015 Big LEAP Year for Allergists
https://www.medscape.com/viewarticle/855905

Dec 21st, 2015 - It was a significant year in allergy and immunology, with the landmark LEAP trial results released, epinephrine injectors recalled, and asthma drugs entering the market in the United States. New guidelines for allergic rhinitis were also issued and the potential role of gut microflora in cutting-edge treatments had specialists talking. Big LEAP: Eating Peanuts in Infancy Reduces Allergy Risk La...

Oral Allergy Syndrome: When an Apple a Day Is Not Advised
https://www.medscape.com/viewarticle/855507

Dec 9th, 2015 - OAS: An Introduction Whoever said "an apple a day keeps the doctor away" clearly did not know anyone with oral allergy syndrome (OAS), also known as "pollen-fruit allergy syndrome." In this condition, immunoglobulin E-mediated hypersensitivity to an environmental allergen triggers food allergy.[1] The most commonly cited example is that of birch pollen-sensitive patients with allergic rhinitis ...

Eating oily fish may help kids avoid nasal allergies
https://www.reuters.com/article/us-health-rhinitis-oilyfish/eating-oily-fish-may-help-kids-avoid-nasal-allergies-idUSKCN0QC1O820150807

Aug 7th, 2015 - (Reuters Health) - Children who eat certain types of fish may be less likely to develop nasal allergies, according to a study from Sweden. Researchers studied what children ate at age eight and then monitored whether they developed nasal inflammation due to allergies or colds by age 16. Regular consumption of oily fish like salmon was linked a reduced risk of allergic rhinitis, or inflammation ...

Nasal Filter: A New Tool in the Fight Against Hay Fever?
https://www.medscape.com/viewarticle/848226

Jul 19th, 2015 - NEW YORK (Reuters Health) - People plagued by seasonal allergic rhinitis might try a new nasal filter to prevent symptoms before they start, the Danish researchers who designed it suggest. Dr. Torben Sigsgaard of Aarhus University Hospital in Denmark, senior author of the paper, called the filter "an easy and simple remediation to prevent allergen exposure during the pollen season for persons s...

AAAAI: Grass allergy tablets show favorable NNT
https://www.mdedge.com/obgyn/article/99010/immunology/aaaai-grass-allergy-tablets-show-favorable-nnt
Bruce Jancin

Apr 22nd, 2015 - HOUSTON – The number needed to treat with Timothy grass sublingual immunotherapy tablets for allergic rhinitis to achieve a clinically meaningful response is 7. 9, Dr.

The Hygiene Hypothesis -- Redefine, Rename, or Just Clean It Up?
https://www.medscape.com/viewarticle/842500

Apr 5th, 2015 - Origin of the Hygiene Hypothesis The "hygiene hypothesis" has been a topic of contention ever since the term was first coined in 1989 by Professor David Strachan (St George's, University of London, London, United Kingdom). Derived from his study showing that a child's risk of developing allergic rhinitis ("hay fever") was inversely related to the number of older siblings in the family,[1] Profe...

Accelerated Subcutaneous Immunotherapy: Should You Provide It in Your Practice?
https://www.medscape.com/viewarticle/842295

Apr 2nd, 2015 - Immunotherapy for Respiratory Allergies Subcutaneous allergy injection therapy (SCIT) has been used to successfully treat respiratory allergy for more than a century. What has changed is the availability of other medications, including the recent availability in the United States of oral immunotherapy. Patients presenting to the allergist's office today may very well have already tried some of ...

Atopy Can Predict Oral Immunotherapy Adverse Event Risk
https://www.medscape.com/viewarticle/840691

Feb 26th, 2015 - HOUSTON — The risk for adverse events during peanut oral immunotherapy is high in people with allergic rhinitis and those who react strongly to a peanut skin-prick test, new research shows. This limitation "needs to be properly addressed before the clinical community begins using it for food allergy," said lead investigator Yamini Virkud, MD, from Massachusetts General Hospital in Boston. "We h...

New Guidelines for Allergic Rhinitis Released
https://www.medscape.com/viewarticle/839130

Feb 2nd, 2015 - Clinicians should treat allergic rhinitis (AR) with intranasal steroids when patients' symptoms impair their quality of life, according to clinical practice guidelines published February 2 in Otolaryngology–Head and Neck Surgery. The guidelines further suggest that clinicians should recommend second-generation oral antihistamines, which are less likely to cause drowsiness, for patients complain...

Guideline clarifies first-line treatment for allergic rhinitis
https://www.mdedge.com/dermatology/article/96849/pediatrics/guideline-clarifies-first-line-treatment-allergic-rhinitis?channel=39313
Mary Ann Moon

Feb 2nd, 2015 - First-line treatment for allergic rhinitis should include intranasal steroids, as well as less-sedating second-generation oral antihistamines for patients whose primary complaints are sneezing and itching, according to a new clinical practice guideline published online Feb. 2 in Otolaryngology–Head and Neck Surgery.

FDA approves pediatric dosage of QNASL
https://www.mdedge.com/familymedicine/article/89593/immunology/fda-approves-pediatric-dosage-qnasl?channel=271
Family Practice News; Deepak Chitnis

Dec 22nd, 2014 - The Food and Drug Administration has approved the 40-mcg dose of QNASL for use in the treatment of nasal symptoms associated with allergic rhinitis in children aged 4-11 years, making it the first waterless nasal allergy spray approved for use in children as young as 4 years old. “Through the availability of QNASL [beclomethasone dipropionate] 40 mcg, we are aiming to aid children and their car.

FDA Approves Pediatric Dosage of QNASL
https://www.mdedge.com/clinicianreviews/article/89651/immunology/fda-approves-pediatric-dosage-qnasl?channel=271
Deepak Chitnis

Dec 22nd, 2014 - The Food and Drug Administration has approved the 40-mcg dose of QNASL for use in the treatment of nasal symptoms associated with allergic rhinitis in children aged 4-11 years, making it the first waterless nasal allergy spray approved for use in children as young as 4 years old. “Through the availability of QNASL [beclomethasone dipropionate] 40 mcg, we are aiming to aid children and their car.

People don’t usually complete allergy shots or drops
https://www.reuters.com/article/us-allergies-immunotherapy/people-dont-usually-complete-allergy-shots-or-drops-idUSKBN0EF26220140604

Jun 4th, 2014 - NEW YORK (Reuters Health) - Doctors may recommend allergy shots or under-the-tongue drops to their patients, but most don’t start the treatments, reports a new study. Researchers also found that among patients who do begin so-called allergen immunotherapy, most don’t complete the full course of therapy, which takes years. The study looked at people with allergic rhinitis, which includes seasona...

FDA Panel Rejects OTC Use of Montelukast (Singulair Allergy)
https://www.medscape.com/viewarticle/824583

May 1st, 2014 - The Nonprescription Drugs Advisory Committee of the US Food and Drug Administration (FDA) has voted against recommending that montelukast (Singulair Allergy, Merck) be approved as an over-the-counter (OTC) drug for the treatment of allergic rhinitis (AR). Montelukast has been a prescription medicine for the treatment of asthma for children and adults since 1998, for seasonal AR since 2002, for ...

FDA Approves Three Sublingual Allergy Meds in a Month
https://www.mdedge.com/clinicianreviews/article/81959/immunology/fda-approves-three-sublingual-allergy-meds-month?channel=231
Whitney McKnight

Apr 28th, 2014 - The Food and Drug Administration has approved Ragwitek, a sublingual treatment for short ragweed pollen–related allergic rhinitis in people aged 18-65 years. This is the first FDA-approved oral therapy for hay fever, with or without conjunctivitis, and the third oral allergy medication approved by the FDA in less than a month.

FDA OKs Ragwitek Hay Fever Tablet
https://www.medpagetoday.com/allergyimmunology/allergy/45316

Apr 18th, 2014 - The FDA approved the ragweed allergy treatment Ragwitek, the third sublingual immunotherapy (SLIT) approval this month. The announcement followed that of Merck's other SLIT agent, the Timothy grass pollen allergy tablet Grastek, on Tuesday and that of Greer's multi-grass pollen immunotherapy tablet Oralair earlier in April. While under-the-tongue drops made off-label from subcutaneous allergy s...

FDA approves Ragwitek, third sublingual allergy med in a month
https://www.mdedge.com/pulmonary-health-hub/article/81738/pulmonology/fda-approves-ragwitek-third-sublingual-allergy-med?channel=284
Whitney McKnight

Apr 17th, 2014 - The Food and Drug Administration has approved Ragwitek, a sublingual treatment for short ragweed pollen–related allergic rhinitis in people aged 18-65 years. This is the first FDA-approved oral therapy for hay fever, with or without conjunctivitis, and the third oral allergy medication approved by the FDA in less than a month.

Merck's ragweed pollen allergy drug gets U.S. approval
https://www.reuters.com/article/us-merck-ragwitek-fda/mercks-ragweed-pollen-allergy-drug-gets-u-s-approval-idUSBREA3G21D20140417

Apr 17th, 2014 - A view shows the U.S. Food and Drug Administration (FDA) logo at the lobby of its headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed (Reuters) - The U.S. Food and Drug Administration has approved Merck & Co’s pollen allergy drug Ragwitek. The tablet, which is administered by placing it under the tongue, is to treat the short ragweed pollen induced allergic rhinitis. (r....

FDA Clears Sublingual Ragwitek for Ragweed Allergy
https://www.medscape.com/viewarticle/823794

Apr 16th, 2014 - The US Food and Drug Administration (FDA) has approved Ragwitek (Merck Sharp & Dohme Corp), the first allergen extract administered under the tongue to treat short ragweed pollen–induced allergic rhinitis, with or without allergic rhinoconjunctivitis, in adults 18 through 65 years of age. Allergic rhinitis affects 10% to 25% of the US population, and short ragweed pollen is one of the most comm...

FDA approves Grastek, second oral allergy therapy
https://www.mdedge.com/chestphysician/article/81684/pulmonology/fda-approves-grastek-second-oral-allergy-therapy?channel=271
Alicia Ault, MDedge News

Apr 15th, 2014 - The Food and Drug Administration has approved Grastek, a sublingual immunotherapy for grass pollen–induced allergic rhinitis with or without conjunctivitis in individuals aged 5-65 years. Grastek (Timothy Grass Pollen Allergen Extract), manufactured by Merck, was unanimously supported by an FDA advisory committee in December and is the second sublingual oral therapy to be approved by the agency.

FDA OKs Grastek Hay Fever Immunotherapy Tablets
https://www.medpagetoday.com/allergyimmunology/allergy/45263

Apr 15th, 2014 - The FDA approved Merck's Grastek tablet for grass pollen allergy Monday, making it the second sublingual oral immunotherapy (SLIT) agent to gain that status. Greer's multi-grass pollen SLIT agent Oralair was approved earlier in the month as the first FDA-accepted alternative to subcutaneous injections, although under-the-tongue drops made off label from subcutaneous extracts have been widely us...

FDA Approves First Grass-pollen Allergy Pill
https://www.mdedge.com/clinicianreviews/article/81665/immunology/fda-approves-first-grass-pollen-allergy-pill?channel=231
Rebecca Kern

Apr 14th, 2014 - Oralair was approved April 1 by the Food and Drug Administration for the treatment of allergic rhinitis; it is the first sublingual allergen extract approved for use in the United States. Oralair is indicated to treat allergic rhinitis with or without eye inflammation that is induced by certain grass pollens in people aged 10-65 years.

FDA OKs Sublingual Grastek for Timothy Grass Pollen Allergy
https://www.medscape.com/viewarticle/823627

Apr 13th, 2014 - The US Food and Drug Administration (FDA) has approved Timothy Grass Pollen Allergen Extract Tablet for Sublingual Use Grastek , Merck & Co, Inc) for the treatment of Timothy grass pollen-induced allergic rhinitis, with or without conjunctivitis, in individuals aged 5 to 65 years, with the understanding that autoinjected epinephrine will be available to patients at home, according to the manufa...

FDA approves Oralair, first grass-pollen allergy pill
https://www.mdedge.com/chestphysician/article/81429/pulmonology/fda-approves-oralair-first-grass-pollen-allergy-pill?channel=271
Rebecca Kern, MDedge News

Apr 2nd, 2014 - Oralair was approved April 1 by the Food and Drug Administration for the treatment of allergic rhinitis; it is the first sublingual allergen extract approved for use in the United States. Oralair is indicated to treat allergic rhinitis with or without eye inflammation that is induced by certain grass pollens in people aged 10-65 years.

FDA OKs Under-the-Tongue Oralair for Hay Fever
https://www.medpagetoday.com/allergyimmunology/allergy/45068

Apr 2nd, 2014 - The FDA approved the first sublingual oral immunotherapy (SLIT) agent, the multi-grass pollen tablet Oralair, drugmaker Greer announced. The indication was for grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for grass pollen-specific IgE antibodies to any of the five grass species contained (Sweet Vernal, Orchard, Perenni...

FDA OKs Oralair, First US Sublingual Allergy Immunotherapy
https://www.medscape.com/viewarticle/822975

Apr 1st, 2014 - The US Food and Drug Administration (FDA) has approved Oralair (Stallergenes, Inc), the first sublingual immunotherapy in the United States to treat multiple grass pollens. The drug is indicated for the treatment of persons aged 10 to 65 years with grass pollen–induced allergic rhinitis with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific immun...

Eye Pain in a Woman With Multiple Health Conditions
https://www.medscape.com/viewarticle/822141

Mar 23rd, 2014 - Clinical Presentation A 58-year-old woman comes to the emergency department because of pain in her right eye that has lasted for the past 2 days. She reports a painful red right eye but denies any discharge, itchiness, or burning. She also reports frontal headaches on the right side. She describes the pain as a 7 out of a possible 10. Her systemic health is remarkable for hypertension, a histor...

Asthma may increase risk of cardiovascular events
https://www.mdedge.com/internalmedicine/article/81065/cardiology/asthma-may-increase-risk-cardiovascular-events?channel=194
Doug Brunk

Mar 19th, 2014 - SAN DIEGO – Having asthma appears to significantly increase your risk for cardiovascular events, while having allergic rhinitis appears to protect your risk for such events, results from a large cohort study demonstrated. Studies of mouse models have suggested that Th1 inflammation "is associated with atherosclerosis and plaque development, while the Th2 or general allergic response seems to be.

Asthma May Increase Risk of Cardiovascular Events
https://www.mdedge.com/clinicianreviews/article/81102/cardiology/asthma-may-increase-risk-cardiovascular-events?channel=284
Doug Brunk

Mar 19th, 2014 - SAN DIEGO – Having asthma appears to significantly increase your risk for cardiovascular events, while having allergic rhinitis appears to protect your risk for such events, results from a large cohort study demonstrated. Studies of mouse models have suggested that Th1 inflammation "is associated with atherosclerosis and plaque development, while the Th2 or general allergic response seems to be.

Immunotherapy for Allergies Halts Infection
https://www.medscape.com/viewarticle/821530

Mar 4th, 2014 - SAN DIEGO — People who get immunotherapy injections for their allergies are less likely to develop infectious diseases such as chronic pharyngitis, nasopharyngitis, sinusitis, diseases of the tonsils and adenoids, and the flu, a new study shows. "Allergic rhinitis is a precursor to the allergic march toward asthma and other respiratory disease," said lead investigator Cheryl Hankin, PhD, presid...

Allergic Rhinitis & Immunotherapy: Hope or Hype
https://www.mdedge.com/clinicianreviews/article/81520/immunology/allergic-rhinitis-immunotherapy-hope-or-hype/page/0/7?channel=271

Mar 1st, 2014 - CONCLUSION For most patients, AR has little morbidity; however, for some whose rhinitis is moderate to severe, the complications can be a concern. If symptoms are not controlled with avoidance and/or medication, AI may be indicated.

Allergic Rhinitis Patients Live Longer
https://www.medscape.com/viewarticle/821205

Feb 28th, 2014 - SAN DIEGO — Their runny noses might drive them crazy, but people with allergic rhinitis are likely to outlive the rest of us, a new study suggests. "We found that allergic rhinitis patients had a decreased risk of heart attack, a decreased risk of stroke and, most strikingly, a decreased risk of all-cause mortality," said lead investigator Angelina Crans Yoon, MD, from the Department of Allergy...

Sublingual Ragwitek Backed FDA Panel for Ragweed Allergy
https://www.medscape.com/viewarticle/819899

Jan 27th, 2014 - The Allergenic Products advisory committee of the US Food and Drug Administration (FDA) voted to recommend MK-3641 (Ragwitek, Merck Sharp & Dohme Corp), an allergen extract from short ragweed (Ambrosia artemisiifolia) pollen, as a sublingual immunotherapy for adults aged 18 to 65 years with ragweed-induced allergic rhinitis (AR) with or without allergic rhinoconjunctivitis (ARC). AR/ARC affects...

Grastek Recommended by FDA Panel for Timothy Grass Allergy
https://www.medscape.com/viewarticle/817771

Dec 11th, 2013 - The Allergenic Products Committee of the US Food and Drug Administration (FDA) voted unanimously to recommend Timothy Grass Pollen Allergen Extract Tablet for Sublingual Use (MK-7243) (Grastek, Merck Sharp & Dohme Corp) for the treatment of Timothy grass pollen–induced allergic rhinitis, with or without conjunctivitis, in individuals aged 5 to 65 years, with the understanding that autoinjected ...

Sublingual Oralair Recommended for Grass Pollen Allergy
https://www.medscape.com/viewarticle/817699

Dec 10th, 2013 - The Allergenic Products advisory committee of the US Food and Drug Administration (FDA) voted unanimously to recommend Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use (Oralair, Stallergenes, Inc) for the treatment of persons aged 10 to 65 years with grass pollen-induced allergic rhinitis or conjunctivitis confirmed ...

Nasacort Allergy Spray Going OTC
https://www.medpagetoday.com/allergyimmunology/allergy/42235

Oct 12th, 2013 - The allergy nasal spray triamcinolone acetonide (Nasacort AQ) has been cleared for over-the-counter sale, drugmaker Sanofi announced. The FDA followed its advisory committee's recommendation to do away with prescriptions for the 24-hour corticosteroid nasal spray for seasonal and year-round nasal allergies. Triamcinolone is the first corticosteroid to gain an OTC approval, though other types of...

Patients With Atopic Dermatitis Exhibit Hypersensitivity Reactions to Allergens
https://www.medscape.com/viewarticle/811675

Sep 26th, 2013 - Cutaneous Delayed-Type Hypersensitivity in Patients With Atopic Dermatitis Malajian D, Belsito DV J Am Acad Dermatol. 2013;69:232-237 Study Summary When confronted with chronic eczematous dermatitis, clinicians should try to differentiate between intrinsic (atopic dermatitis [AD]) and extrinsic (allergic or irritant contact dermatitis) causes. AD is a chronic, recurrent dermatitis associated wi...

OTC Nasacort to Get FDA Panel Scrutiny
https://www.medpagetoday.com/allergyimmunology/allergy/40728

Jul 29th, 2013 - WASHINGTON -- FDA staff reviewers had few questions about making allergy nasal spray triamcinolone acetonide (Nasacort AQ) available for over-the-counter (OTC) sales; later this week an advisory committee will look at the issue. Triamcinolone acetonide (TAA) is a "good candidate" for the treatment of seasonal and perennial allergic rhinitis in an OTC setting, FDA staff reviewers said in documen...

Ragweed Allergy Relieved by Daily Oral Immunotherapy
https://www.medscape.com/viewarticle/803997

May 9th, 2013 - Symptoms of ragweed allergy may be reduced with daily sublingual immunotherapy, according to a new, multicenter study published in the May issue of the Journal of Allergy and Clinical Immunology. The new study, led by Peter S. Creticos, MD, from Johns Hopkins University School of Medicine in Baltimore, Maryland, evaluated the safety and efficacy of a sublingual allergy immunotherapy tablet (AIT...

Allergen Immunotherapy: Best Practices
https://www.medscape.com/viewarticle/803436

May 5th, 2013 - Editor's Note Allergen-specific immunotherapy has been used to treat allergic rhinitis and asthma for more than a century. The long-term efficacy of this therapy, most often used for patients with allergic disease who do not respond adequately to medications or avoidance measures, has been reaffirmed in several recently published research papers. Medscape interviewed Linda Cox, MD, President of...

FDA OKs Carbinoxamine ER for Allergic Rhinitis in Children
https://www.medscape.com/viewarticle/781921

Apr 2nd, 2013 - The US Food and Drug Administration (FDA) has approved carbinoxamine maleate extended-release (Karbinal ER, Tris Pharma), the first liquid, sustained-release histamine-H1 receptor blocker indicated for the treatment of seasonal and perennial allergic rhinitis in children aged 2 years and older, the company said. The drug will be available in a 4 mg/5 mL oral suspension. It is dosed once every 1...

SLIT Has Value in Allergy, Asthma
https://www.medpagetoday.com/allergyimmunology/allergy/38094

Mar 26th, 2013 - Action Points Sublingual immunotherapy (SLIT) can be an effective treatment for asthma and allergic rhinitis. Point out that the review warned that higher-quality studies are needed to answer certain questions about SLIT, such as optimal dosing strategies and duration of treatment. Sublingual immunotherapy (SLIT) can be an effective treatment for asthma and allergic rhinitis, researchers found....